Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 2/2012

01-04-2012 | Evolving Therapies (RM Bukowski, Section Editor)

The Biology and Clinical Features of Non–small Cell Lung Cancers with EML4-ALK Translocation

Authors: Rathi N. Pillai, Suresh S. Ramalingam

Published in: Current Oncology Reports | Issue 2/2012

Login to get access

Abstract

The anaplastic lymphoma kinase (ALK) acts as a dominant oncogenic driver following chromosomal rearrangements in certain cancers including non–small cell lung cancer (NSCLC). NSCLC with ALK translocation occurs in a specific subset of patients and results in unique clinical features. Crizotinib is a small molecule inhibitor of ALK kinase that has recently been approved by the FDA for the treatment of patients with ALK-positive NSCLC. Treatment with crizotinib results in clinical benefit rate of 85%–90% and a median progression-free survival of 9–10 months for this molecular subset of patients. Ongoing studies will define the impact of crizotinib on overall survival and provide insights into the resistance mechanisms and potential activation of alternate pathways. Heat shock protein 90 inhibitors also appear promising in the treatment of ALK-positive NSCLC patients, based on early results. This article reviews the characteristics, treatment, and ongoing research in patients with ALK-positive NSCLC.
Literature
1.
Ambrogio C, Voena C, Manazza AD, et al. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. Cancer Res. 2008;68(21):8899–907.PubMedCrossRef
2.
Chiarle R, Voena C, Ambrogio C, et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8(1):11–23.PubMedCrossRef
3.
4.
Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–8.PubMedCrossRef
5.
Mok TS, Wu YL, Thongprasert S. Phase III, randomised, open-label, first-line study of gefitinib vs carboplatin/paclitaxel in clinically selected patients with advanced nonsmall-cell lung cancer (IPASS). . in ESMO Conference. 2008. Stockholm.
6.
Rosell R, Gervais R, Vergnenegre A, et al, Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutaitons: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial, in ASCO. 2011: Chicago.
7.
• Soda M, Choi YL, Enomoto M, et al., Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 2007. 448(7153): p. 561-6. This is the initial report describing the identification of the EML4-ALK translocation in a lung adenocarcinoma patient and the transforming activity of the resulting constitutively activated kinase.
8.
Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A. 2008;105(50):19893–7.PubMedCrossRef
9.
• Shaw, AT, Yeap BY, Mino-Kenudson M, et al., Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol, 2009. 27(26): p. 4247-53. This paper describes the clinical features of the largest cohort to date of ALK-rearranged lung cancer patients.
10.
Sasaki T, Rodig SJ, Chirieac LR, Janne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. 2010;46(10):1773–80.PubMedCrossRef
11.
Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97(5):339–46.PubMedCrossRef
12.
Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010;17(3):889–97.PubMedCrossRef
13.
Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008;3(1):13–7.PubMedCrossRef
14.
Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Annals of Surgical Oncology. 2010;17(3):889–97.CrossRef
15.
Inamura K, Takeuchi K, Yogashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 2009;22(4):508–15.PubMedCrossRef
16.
Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009;15(16):5216–23.PubMedCrossRef
17.
Yang J, Zhang X, Su J, et al. Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. in ASCO. 2011. Chicago.
18.
Paik JH, Choe G, Kim H, et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol. 2011;6(3):466–72.PubMedCrossRef
19.
Yi ES, Boland JM, Maleszewski JJ, et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol. 2011;6(3):459–65.PubMedCrossRef
20.
Takeuchi K, Choi YL, Soda M, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res. 2008;14(20):6618–24.PubMedCrossRef
21.
Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14(13):4275–83.PubMedCrossRef
22.
• Kwak EL, Bang YJ, Camidge DR, et al., Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med, 2010. 363(18): p. 1693-703. This article reports initial phase 1 data demonstrating the therapeutic efficacy of ALK blockade by crizotinib.
23.
Camidge DR, Bang Y, Kwak EL, et al. Progression-Free Survival (PFS) from a Phase 1 Study of Crizotinib (PF-02341066) in Patients with ALK-Positive Non-Small Cell Lung Cancer (NSCLC). in ASCO. 2011. Chicago.
24.
Shaw AT, Yeap BY, Solomon BJ, et al, Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls, in ASCO. 2011: Chicago.
25.
Crino L, Kim D, Riely GJ, et al, Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005, in ASCO. 2011: Chicago.
26.
Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010;363(18):1734–9.PubMedCrossRef
27.
Katayama R, Khan YM, Benes C, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A. 2011;108(18):7535–40.PubMedCrossRef
28.
Sakamoto H, Tsukaguchi T, Hiroshima S, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011;19(5):679–90.PubMedCrossRef
29.
Sequist LV, Gettinger S, Senzer NN, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol. 2010;28(33):4953–60.PubMedCrossRef
30.
Normant E, Paez G, West KA, et al. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene. 2011;30(22):2581–6.PubMedCrossRef
31.
Wong K, Koczywas M, Goldman JW, et al, An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC), in ASCO. 2011: Chicago.
32.
Kris MG, Johnson BE, Kwiatkowski DJ, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC), in ASCO. 2011: Chicago.
Metadata
Title
The Biology and Clinical Features of Non–small Cell Lung Cancers with EML4-ALK Translocation
Authors
Rathi N. Pillai
Suresh S. Ramalingam
Publication date
01-04-2012
Publisher
Current Science Inc.
Published in
Current Oncology Reports / Issue 2/2012
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-012-0213-4

Other articles of this Issue 2/2012

Current Oncology Reports 2/2012 Go to the issue

Head and Neck Cancers (EY Hanna, Section Editor)

Current Progress in Adaptive Radiation Therapy for Head and Neck Cancer

Head and Neck Cancers (EY Hanna, Section Editor)

Salivary Gland Cancers: Biology and Molecular Targets for Therapy

Pediatric Oncology (S Epelman, Section Editor)

Late Effects in Cancer Survivors: “The Shared Care Model”

Head and Neck Cancers (EY Hanna, Section Editor)

The Clinical Importance of Quality-of-Life Scores in Patients with Skull Base Tumors: A Meta-Analysis and Review of the Literature

Pediatric Oncology (S Epelman, Section Editor)

Impact of Molecular Biology Studies on the Understanding of Brain Tumors in Childhood

Head and Neck Cancers (EY Hanna, Section Editor)

Functional Outcomes after Chemoradiotherapy of Laryngeal and Pharyngeal Cancers
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits